Europe NGS Market (2025-2032)
The Europe NGS Market is expected to grow at a CAGR of 14.8% from 2025 to 2032 to reach $6.40 billion by 2032.
- Published
- Jan 2025
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 1041061
- Base year
- 2024
- 2032 · FORECAST
- $6.40B
- 2032
- $6.40B
- CAGR 2025–2032
- 14.8%
2024 baseline · 2025–2032 forecast at 14.8% CAGR · hover a bar for the value
Key highlights
Consumables Segment to Account for the Largest Share of the Market in 2025
Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2025
Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2025
Research and Other Applications Segment to Account for the Largest Share of the Market in 2025
Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Europe NGS Market in 2025
Germany to Account for the Largest Market Share in 2025
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 6.40 billion |
| CAGR (2025–2032) | 14.8% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Offering: Library Preparation & Target Enrichment, Quality Control · By Sequencing Type: Targeted Genome Sequencing, Whole Genome Sequencing, Whole Exome Sequencing · By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing, DNA nanoball sequencing · By Application: Research Applications Drug Discovery, Agriculture & Animal Research, Other Research Applications, Reproductive Health Diagnosis, Oncology, Infectious Diseases, Other Clinical Applications · By End User: Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic Institutes & Research Centers, Other End Users · By Type: Genome, Exome, Targeted |
| Countries Covered | Europe (Germany, France, U.K., Italy, Spain, Switzerland, Rest of Europe) |
| Key Companies | Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Agilent Technologies, Inc., California Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Genomics, Inc. |
Report overview
Segments covered: offering, sequencing type, technology, application, end user, type. Regions: Europe.
The field of genomics has surpassed expectations over the past three decades due to massive changes in technology that allowed researchers to interrogate larger pieces of the human genome. Next-generation Sequencing (NGS) is one such massively parallel or deep sequencing technology that helps identify the sequence of nucleotides in DNA/RNA. Due to its high-throughput production, efficient instrument run, and lower cost compared to the traditional Sanger first-generation sequencing method, NGS is highly preferred for large-scale genomic and transcriptomic sequencing.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.
Report infographic
Market dynamics
1 factors across 1 forceThe Increasing Applications of NGS Create an Opportunity for the Market
NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers. For instance, in February 2025, Dxcover Limited (U.K.) raised USD 11.9 million in funding to support the development of a liquid biopsy technology platform for the diagnosis of early-stage cancers, which includes colorectal and brain cancers. NGS-based liquid biopsy analysis finds a small quantity of remaining tumor DNA or RNA in post-treatment samples, which enables responses to treatment monitoring and early disease detection, creating growth opportunities for the players operating in the NGS market.
Table of contents
13 chapters · 99 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Sequencing Type | Targeted Genome Sequencing | — |
| By Technology | Sequencing by Synthesis | — |
| By Application | Research and Other Applications | — |
| By End User | Pharmaceutical & Biotechnology Companies | — |
By Offering
- Consumables Segment to Account for the Largest Share of the Market in 2025
- The consumables segment is expected to account for the largest share of the Europe NGS market.
- The recurring use of consumables and advancements in target enrichment protocols and associated consumables.
- Many companies are focusing on partnerships to enhance their consumable offerings.
- For instance, in February 2022, QIAGEN N.V.
- (Netherlands) partnered with Element Biosciences, Inc. (U.S.) to validate a selection of its NGS library prep and target enrichment offerings on the latter’s AVITI System.
By Sequencing Type
- Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2025
- The targeted genome sequencing segment is expected to account for the largest share of the Europe NGS market.
- The large share of this segment is attributed to low sequencing costs as compared to other sequencing technologies, higher sensitivity of the technique to call variants, and advancements in targeted genome sequencing technologies.
- Advancements in targeted genome sequencing have improved the diagnosis of monogenic intestinal and pediatric disorders.
- In addition to disease diagnosis, this technology has enabled researchers to study gene-drug associations, which has helped researchers design gene-specific drugs with high specificity.
By Technology
- Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2025
- The sequencing by synthesis segment is expected to account for the largest share of the Europe NGS market.
- The key factors supporting the large market share of this segment are low sequencing costs compared to other sequencing technologies such as ion semiconductor sequencing, nanopore sequencing, and many others, higher sensitivity of the technique to call variants, and proven results in identifying primary immunodeficiencies and specific gene-associated diseases.
By Application
- Research and Other Applications Segment to Account for the Largest Share of the Market in 2025
- The research and other applications segment is expected to account for the largest share of the Europe NGS market.
- The increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, the increasing NGS-based research, and the growing prevalence of genetic disorders.
- For instance, according to the data published by the German Center for Lung Research in July 2025, in Germany, approximately 2,500 newborns were affected with cystic fibrosis in 2022.
By End User
- Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Europe NGS Market in 2025
- The pharmaceutical & biotechnology segment is expected to account for the largest share of the Europe NGS market.
- The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes and increasing research for drug discovery with widening NGS applications, rising incidence of chronic diseases, and increasing R&D spending by pharmaceutical & biotechnology companies.
- For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) data, in 2020, global pharmaceutical R&D spending was USD 189 billion, which is expected to increase up to USD 202 million by 2025.
- NGS enables pharmaceutical & biotechnology companies to identify and validate biomarkers that can be used in developing new diagnostic tests and therapies, which drives the adoption of NGS among pharmaceutical & biotechnology companies.
Geographic analysis
Europe
Largest shareIn 2025, Germany is expected to account for the largest share of the Europe NGS market. The large share is primarily attributed to the increasing number of sequencing projects, growing research for the development of personalized medicine in the country, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, growing research activities for developing personalized medicines, and the rising prevalence of cancer. For instance, according to GLOBOCAN, 19.3 million people were diagnosed with cancer in 2020. This number is expected to rise to 24.6 million by 2032. NGS has helped to make it easy for researchers to identify and clarify hundreds of genes linked to cancer; these discoveries are certain to contribute to the identification of new therapeutic targets. Germany to Account for the Largest Market Share in 2025
Competitive landscape
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- California Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Genomics, Inc.
Frequently asked questions
This study offers a detailed assessment of the Europe NGS market, including the market size & forecast for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
Cite this report
Meticulous Research. (2025). Europe NGS Market - Opportunity Analysis and Industry Forecasts (2025-2032) (Report No. MRHC - 1041061). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/europe-ngs-market-5744